Clinical Trials Directory

A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus Caspofungin Followed by Voriconazole in the Treatment of Candidemia and Other Invasive Candida Infections

The purpose of the study is to compare the safety and efficacy of Isavuconazole versus caspofungin followed by voriconazole in the treatment of candidemia and other invasive Candida infections.

Stanford is now accepting new patients for this trial.

Investigator(s):

Intervention(s):

  • drug : Isavuconazole
  • drug : Voriconazole
  • drug : Caspofungin

Phase: Phase 3

Eligibility

Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Patients with candidemia or with an invasive Candida infection - Presence of fever, hypothermia or other appropriate local sign of infection - Female patients must be non-lactating and at no risk of pregnancy

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Physician Referrals
650-723-0822
Recruiting

Footer Links: